CompletedNot Applicable

Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea

South Korea2,758 participantsStarted 2021-12-20

Plain-language summary

The objective of this study is to evaluate the real-world prescription patterns of Palbociclib in breast cancer (BC) patients who were treated with Palbociclib in combination with AI as a 1st line of therapy using the national health insurance claims data in South Korea.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who were prescribed with palbociclib in combination with AI for at least 1 cycle during the index period * Patients who were diagnosed with BC during the index period Exclusion Criteria: * Male * Prescribed with palbociclib during 12-month period preceding the index date

What they're measuring

Total treatment duration and cycle for Palbociclib

Timeframe: From index date (Index date: 06 Nov 2012 to 30 Sep 2020) to the end date of last palbociclib prescription (maximum of 34.8 months from the index date)

Trial details

NCT IDNCT05132101

SponsorPfizer

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2022-03-14

View on ClinicalTrials.gov More Metastatic Breast Cancer trials